With increased powers, Health Commissioner-designate Stella Kyriakides is tasked with striking a difficult balance between making sure there is a steady supply of affordable medicines and ensuring that EU pharma industry remains a world leader in innovation.
MBC is more than just a lethal disease. It has a toxic impact on most if not to say all aspects of MBC patient’s lives. A situation that is aggravated by their underdog position, even in the breast cancer community itself.
We have to increase the survival rate for metastatic breast cancer patients. Science has done its part and hopefully will keep up. Policy is supposed to support it, requiring a continuous effort among multiple actors, argues MEP Alberto Cirio.
Metastatic breast cancer (MBC) has long been disregarded by advocacy groups, researchers and policymakers. As a result, little is known about the scope of the disease, its economic burden and the best way to treat it.
Medical data owners should cooperate and no longer monopolise their databases and policy makers should consider what is most important: protecting the privacy of the present MBC patients or allowing privacy exceptions to save the lives of future MBC patients, writes Suzanne Leempoels.
A group of metastatic breast cancer experts has urged policymakers to empower patients with greater choice and participation in their treatment and care, to improve the quality of life of patients, their carers and families.
Metastatic breast cancer (MBC) kills half a million women in the EU every year, yet progress on the quality of life and survival time of MBC patients remains elusive. MEPs addressed the need to improve patient outcomes with a policy roadmap launched on Tuesday (17 October).